Latest Industry Insights

Genomic data company PetaGene recently sounded a warning that Genome UK, the UK government’s recently announced genomic healthcare strategy, needs to address important data handling challenges to maintain public trust. To find out more, Technology Networks spoke to PetaGene’s co-founder and chief commercial officer, Vaughan Wittorff, PhD, and co-founder and chief executive officer, Dan Greenfield, PhD.

With demand for workplace drug and alcohol testing growing in many countries and the increasing liberalization of drug laws across the world, the market is predicted to grow considerably over the next decade. Here we share a Q&A with John Wick, CEO of Cansford Laboratories, who pioneered the use of hair testing in the UK around 25 years ago.

In a recent study, CTCs were harvested to investigate the causes of brain metastasis in non-small cell lung cancer patients. We spoke to Andrew Newland, CEO, ANGLE, to learn more about the study, the challenges of harvesting CTCs and how the Parsortix system overcomes some of these challenges.

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. 2020 has brought mixed news for AC Immune's therapeutics, including promising safety data for their anti-Alzheimer's disease vaccine candidate. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.

How do we take our understanding of the different stages of the omics cascade to the next level? We analyze them simultaneously. With the recent launch of its Chromium Single Cell Multiome ATAC + Gene Expression solution, 10x Genomics is making advances towards that goal. Technology Networks spoke with Ben Hindson to learn more.

Psilocybin’s emergence as a valuable tool for mental health research has been a huge breakthrough for the field. But how do researchers get their hands on this heavily regulated substance? Technology Networks talked to Tim Moore, CEO of Havn Life Sciences, a company that produces psychoactive compounds from plants and fungi, to find out more.

Technology Networks had the pleasure of speaking with Ross Macdonald, CEO of Cynata Therapeutics, to learn more about the challenges of manufacturing therapeutic MSCs and how the Cymerus technology overcomes these.

The role that psychedelic therapeutics could play in tackling many intractable mental health conditions has finally been recognized by mainstream medicine. To find out more, we spoke to Carol Routledge, Chief Medical & Scientific Officer at Small Pharma.

Emerging technologies have the potential to significantly transform the laboratory environment. In this Insight, Labforward's Phoebe Chubb outlines what the lab of the future will look like.

One of the biggest challenges that scientists and healthcare professionals are facing during the COVID-19 pandemic is the high rate of clinical variability. Whilst some patients present as asymptomatic, others are developing more severe symptoms such as pneumonia, and some cases are ultimately proving fatal. Why? We speak with Dr Salvatore Viscomi to learn more.